Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

BACKGROUND: Patients with cancer are at high risk for severe courses of COVID-19. Based on (pre-)clinical data suggesting a potential protective effect due to the immunomodulating properties of azithromycin, we have initiated a prospective randomized trial. METHODS: This randomized, single-center, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mair, Maximilian J., Maj-Hes, Agnieszka, Nussbaumer-Pröll, Alina, Puhr, Rainer, Christenheit, Agnieszka, Troch, Marlene, Puhr, Hannah C., Starzer, Angelika M., Steindl, Ariane, Eberl, Sabine, Haslacher, Helmuth, Perkmann, Thomas, Minichsdorfer, Christoph, Prager, Gerald W., Lamm, Wolfgang W., Berghoff, Anna S., Kiesewetter, Barbara, Zeitlinger, Markus, Preusser, Matthias, Raderer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924847/
https://www.ncbi.nlm.nih.gov/pubmed/36782325
http://dx.doi.org/10.1186/s13027-023-00487-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924847/
https://www.ncbi.nlm.nih.gov/pubmed/36782325
http://dx.doi.org/10.1186/s13027-023-00487-x

Ejemplares similares